Advertisement

Genetic Engineering: Tinkering with the Human Body

  • H. G. StratmannEmail author
Chapter
Part of the Science and Fiction book series (SCIFICT)

Abstract

Science fiction sometimes includes a human character who, by chance or design, is biologically superior in at least one distinct way to a conventional example of H. sapiens. These “improvements” may be due to natural processes, such as the slow changes produced by evolution. For example, modern humans have brains over twice as large as members of their ancestors, H. habilis, over 1 million years ago. While the latter had only enough intelligence to create simple stone tools, ours has increased enough to create a more complex and at times deadly technology.

Keywords

Human Immunodeficiency Virus Gene Therapy Genetic Modification Chronic Granulomatous Disease Marfan Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hudson K. Genomics, health care, and society. N Engl J Med. 2011;365(11):1033–41.CrossRefPubMedGoogle Scholar
  2. 2.
    Lewin B. Part 1: DNA as information. Genes VI. Oxford: Oxford University Press; 1997. pp. 49–150.Google Scholar
  3. 3.
    Mendel G. Experiments on plant hybridization. 1865. http://www.mendelweb.org/Mendel.html. Accessed 6 May 2015.
  4. 4.
    van Cleve F. The fabulous fruits of Mendel’s garden. Analog Sci Fict Fact. 2013;133(7/8):71–7.Google Scholar
  5. 5.
    Sen S, Kar D. Mendelian inheritance. In: Johri B, ed. Cytology and genetics. Oxford: Alpha Science International Ltd.; 2005. pp. 109–24.Google Scholar
  6. 6.
    Sen S, Kar D. Gene expression and interaction. In: Johri B, ed. Cytology and genetics. Oxford: Alpha Science International Ltd.; 2005. pp. 125–41.Google Scholar
  7. 7.
    Korf B. Genetics. In: Runge M, Patterson C, editors. Principles of molecular medicine. 2nd ed. New York: Humana Press; 2006. pp. 3–8.CrossRefGoogle Scholar
  8. 8.
    Bolar N, Van Laer L, Loeys B. Marfan syndrome: from gene to therapy. Curr Opin Pediatr. 2012;24:498–504.CrossRefPubMedGoogle Scholar
  9. 9.
    von Kodolitsch Y, Robinson PN. Marfan syndrome: an update of genetics, medical and surgical management. Heart. 2007;93(6):755–60.CrossRefGoogle Scholar
  10. 10.
    McCandless S, Cassidy S. Nontraditional inheritance. In: M, Patterson C, editors. Principles of molecular medicine. 2nd ed. New York: Humana Press; 2006:9–18.Google Scholar
  11. 11.
    Zinn A. Sex chromosome disorders. In: Runge M, Patterson C, editors. Principles of molecular medicine. 2nd ed. New York: Humana Press; 2006. pp. 446–52.CrossRefGoogle Scholar
  12. 12.
    Pertea M, Salzbert S. Between a chicken and a grape: estimating the number of human genes. Genome Biol. 2010;11:206–12.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Pollard T, Earnshaw W, Lippincott-Schwartz J. Introduction to cells. Cell Biology. 2nd ed. Philadelphia: Saunders Elsevier; 2008. pp. 3–16.Google Scholar
  14. 14.
    Pollard T, Earnshaw W, Lippincott-Schwartz J. DNA packaging in chromatin and chromosomes. Cell Biology. 2nd ed. Philadelphia: Saunders Elsevier; 2008. pp. 209–30.Google Scholar
  15. 15.
    White D, Rabago-Smith M. Genotype-phenotype associations and human eye color. J Human Genet. 2011;56:5–7.CrossRefGoogle Scholar
  16. 16.
    Cavazzana-Calvo M. Gene therapy of Human Severe Combined Immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669–72.CrossRefPubMedGoogle Scholar
  17. 17.
    Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012—an update. J Gene Med. 2013;15(2):65–77.CrossRefPubMedGoogle Scholar
  18. 18.
    Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay J, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2000;346(16):1185–93.CrossRefGoogle Scholar
  19. 19.
    Mukherjee S, Thrasher AJ. Gene therapy for PIDs: progress, pitfalls and prospects. Gene. 2013;525(2):174–81.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Cideciyan AV, Jacobson SG, Beltran WA, Sumaroka A, Swider M, Iwabe S, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A. 2013;110(6):E517–25.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Dong A, Rivella S, Breda L. Gene therapy for hemoglobinopathies: progress and challenges. Transl Res. 2013;161(4):293–306.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    McClements ME, MacLaren RE. Gene therapy for retinal disease. Transl Res. 2013;161(4):241–54.CrossRefPubMedGoogle Scholar
  23. 23.
    Wivel N, Walters L. Germ-line gene modification and disease prevention: some medical and ethical perspectives. Science. 1993;262:533–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Vannucci L, Lai M, Chiuppesi F, Ceccherini-Nelli L, Pistello M. Viral vectors: a look back and ahead on gene transfer technology. New Microbiologica 2013;36:1–22.PubMedGoogle Scholar
  25. 25.
    Zanjani ED. Prospects for in utero human gene therapy. Science. 1999;285(5436):2084–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Guella I, Asselta R, Ardissino D, Merlini PA, Peyvandi F, Kathiresan S, et al. Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population. J Lipid Res. 2010;51(11):3342–9.CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014;370(10):901–10.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Bennett J. Gene therapy for color blindness. N Engl J Med. 2009;361(25):2483–4.CrossRefPubMedGoogle Scholar
  29. 29.
    Suzuki K, Matsubara H. Recent advances in p53 research and cancer treatment. J Biomed Biotechnol. 2011;2011:978312.PubMedCentralPubMedGoogle Scholar
  30. 30.
    Kalburgi S. Recent gene therapy advancements for neurological diseases. Discov Med. 2013;15(81):111–9.Google Scholar
  31. 31.
    Nienhuis AW. Development of gene therapy for blood disorders: an update. Blood. 2013;122(9):1556–64.CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Giatsidis G, Dalla Venezia E, Bassetto F. The role of gene therapy in regenerative surgery: updated insights. Plast Reconstr Surg. 2013;131(6):1425–35.CrossRefPubMedGoogle Scholar
  33. 33.
    Marshall E. Gene therapy on trial. Science. 2000;288(5468):951–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao G-p, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1–2):148–58.CrossRefPubMedGoogle Scholar
  35. 35.
    Maguire A, Simonelli F, Pierce E, Pugh E, Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med. 2008;358(21):2240–8.CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, et al. AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. The Lancet Neurology. 2011;10(4):309–19.CrossRefPubMedGoogle Scholar
  37. 37.
    Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang G, Berry C, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2010;363:355–64.CrossRefPubMedCentralPubMedGoogle Scholar
  38. 38.
    Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012;4(132):132ra53.CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Kerkar SP. Model T cells: a time-tested vehicle for gene therapy. Front Immunol. 2013;4:304.CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Naldini L. Medicine. A comeback for gene therapy. Science. 2009;326(5954):805–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Leboulch P. Gene therapy: primed for take-off. Nature. 2013;500:280–1.CrossRefPubMedGoogle Scholar
  42. 42.
    Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341:1233158-1-11.CrossRefGoogle Scholar
  43. 43.
    Trobridge GD, Horn PA, Beard BC, Kiem HP. Large animal models for foamy virus vector gene therapy. Viruses. 2012;4(12):3572–88.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Chen Z, Lin Y, Yang F, Jiang L, Ge S. Gene therapy for cardiovascular disease mediated by ultrasound and microbubbles. Cardiovasc Ultrasound. 2013;11(11). doi:10.1186/1476-7120-11-11.Google Scholar
  45. 45.
    Kazuki Y, Hoshiya H, Takiguchi M, Abe S, Iida Y, Osaki M, et al. Refined human artificial chromosome vectors for gene therapy and animal transgenesis. Gene Ther. 2011;18(4):384–93.CrossRefPubMedCentralPubMedGoogle Scholar
  46. 46.
    Nowakowski A, Andrzejewska A, Janowski M, Walczak P, Lukomska B. Genetic engineering of stem cells for enhanced therapy. Acta Neurobiol Exp. 2013;73:1–18.Google Scholar
  47. 47.
    Raftery R, O’Brien FJ, Cryan SA. Chitosan for gene delivery and orthopedic tissue engineering applications. Molecules. 2013;18(5):5611–47.CrossRefPubMedGoogle Scholar
  48. 48.
    Jin L, Zeng X, Liu M, Deng Y, He N. Current progress in gene delivery technology based on chemical methods and nano-carriers. Theranostics. 2014;4(3):240–55.CrossRefPubMedCentralPubMedGoogle Scholar
  49. 49.
    Paul M, van Dolleweerd C, Drake PMW, Reljic R, Thangaraj H, Barbi T, et al. Molecular pharming: future targets and aspirations. Human Vaccines. 2011;7(3):375–82.CrossRefPubMedCentralPubMedGoogle Scholar
  50. 50.
    Melo E, Canavessi A, Franco M, Rumpf R. Animal transgenesis: state of the art and applications. J Appl Genet. 2007;48:47–61.CrossRefPubMedGoogle Scholar
  51. 51.
    Gene Therapy Clinical Trials Worldwide. http://www.wiley.com/legacy/wileychi/genmed/clinical/. Accessed 6 May 2015.
  52. 52.
    Kaiser J. Gene therapists celebrate a decade of progress. Science. 2011;334:29–30.CrossRefPubMedGoogle Scholar
  53. 53.
    Verma IM. Medicine. Gene therapy that works. Science. 2013;341(6148):853–5.CrossRefGoogle Scholar
  54. 54.
    Walker MC, Schorge S, Kullmann DM, Wykes RC, Heeroma JH, Mantoan L. Gene therapy in status epilepticus. Epilepsia. 2013;54(Suppl 6):43–5.CrossRefPubMedGoogle Scholar
  55. 55.
  56. 56.
    Glybera. http://www.uniqure.com/pipeline/glybera/. Accessed 6 May 2015.
  57. 57.
    What price affordable access? Nat Biotechnol. 2013;31(6):467.Google Scholar
  58. 58.
    McCarthy J, McLeod H, Ginsburg G. Genomic medicine: a decade of successes, challenges, and opportunities. Sci Transl Med. 2013;5(189 sr4):1–17.Google Scholar
  59. 59.
    Plon S. Cancer genetics and molecular oncology. In: Runge M, Patterson C, editors. Principles of molecular medicine. 2nd ed. New York: Humana Press; 2006. pp. 27–33.CrossRefGoogle Scholar
  60. 60.
    Huang Y, Davidson N. Breast Cancer. In: Runge M, Patterson C, editors. Principles of molecular medicine. 2nd ed. New York: Humana Press; 2006:728. p. 35.Google Scholar
  61. 61.
    BRCA1 and BRCA2. Cancer risk and genetic testing fact sheet. http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA. Accessed 6 May 2015.
  62. 62.
    Davies G, Tenesa A, Payton A, Yang J, Harris SE, Liewald D, et al. Genome-wide association studies establish that human intelligence is highly heritable and polygenic. Mol Psychiatry. 2011;16(10):996–1005.CrossRefPubMedCentralPubMedGoogle Scholar
  63. 63.
    Research CoSMa. Sleep disorders and sleep deprivation: an unmet public health problem. Washington: National Academies Press; 2006.Google Scholar
  64. 64.
    Crocker A, Sehgal A. Genetic analysis of sleep. Genes Dev. 2010;24(12):1220–35.CrossRefPubMedCentralPubMedGoogle Scholar
  65. 65.
    Schenkein J, Montagna P. Self management of fatal familial insomnia. Part 1: What is FFI? MedGenMed. 2006;8:65.PubMedCentralPubMedGoogle Scholar
  66. 66.
    Faraut B, Boudjeltia KZ, Vanhamme L, Kerkhofs M. Immune, inflammatory and cardiovascular consequences of sleep restriction and recovery. Sleep Med Rev. 2012;16(2):137–49.CrossRefPubMedGoogle Scholar
  67. 67.
    Parish JM. Genetic and immunologic aspects of sleep and sleep disorders. Chest. 2013;143(5):1489–99.CrossRefPubMedCentralPubMedGoogle Scholar
  68. 68.
    Herculano-Houzel S. Neuroscience. Sleep it out. Science. 2013;342(6156):­316–7.CrossRefPubMedGoogle Scholar
  69. 69.
    Underwood E. Sleep: the brain’s housekeeper? Science. 2013;342:301.CrossRefPubMedGoogle Scholar
  70. 70.
    Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373–7.CrossRefPubMedGoogle Scholar
  71. 71.
    Edkins R, Cheek D. Pharmacogenetics. In: Runge M, Patterson C, editors. Principles of molecular medicine. 2nd ed. New York: Humana Press; 2006. pp. 34–8.CrossRefGoogle Scholar
  72. 72.
    Table of Pharmacogenomic Biomarkers in Drug Labeling. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. Accessed 6 May 2015.
  73. 73.
    Ong FS, Deignan JL, Kuo JZ, Bernstein KE, Rotter JI, Grody WW, et al. Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics. 2012;13(4):465–75.CrossRefPubMedCentralPubMedGoogle Scholar
  74. 74.
    Wells QS, Delaney JT, Roden DM. Genetic determinants of response to cardiovascular drugs. Curr Opin Cardiol. 2012;27(3):253–61.CrossRefPubMedGoogle Scholar
  75. 75.
    Joly Y, Ngueng Feze I, Simard J. Genetic discrimination and life insurance: a systematic review of the evidence. BMC Med. 2013;11:25.CrossRefPubMedCentralPubMedGoogle Scholar
  76. 76.
    Kimelman Bleich N, Kallai I, Lieberman JR, Schwarz EM, Pelled G, Gazit D. Gene therapy approaches to regenerating bone. Adv Drug Deliv Rev. 2012;64(12):1320–30.CrossRefPubMedGoogle Scholar
  77. 77.
    Zaneveld J, Wang F, Wang X, Chen R. Dawn of ocular gene therapy: implications for molecular diagnosis in retinal disease. Sci China Life Sci. 2013;56(2):125–33.CrossRefPubMedGoogle Scholar
  78. 78.
    Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, et al. Progress in gene therapy for neurological disorders. Nat Rev Neurol. 2013;9(5):277–91.CrossRefPubMedCentralPubMedGoogle Scholar
  79. 79.
    Willett K, Bennett J. Immunology of AAV-mediated gene transfer in the eye. Front Immunol. 2013;4:261.CrossRefPubMedCentralPubMedGoogle Scholar
  80. 80.
    Benedetti S, Hoshiya H, Tedesco FS. Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies. FEBS J. 2013;280(17):4263–80.CrossRefPubMedGoogle Scholar
  81. 81.
    Chen G, Twyman R, Manji H. p11 and gene therapy for severe psychiatric disorders: a practical goal? Sci Transl Med. 2010;2(54):54 ps51CrossRefGoogle Scholar
  82. 82.
    Ozomaro U, Wahlestedt C, Nemeroff C. Personalized medicine in psychiatry: problems and promises. BMC Med. 2013;11:132.CrossRefPubMedCentralPubMedGoogle Scholar
  83. 83.
    Picker JD, Walsh CA. New innovations: therapeutic opportunities for intellectual disabilities. Ann Neurol. 2013;74(3):382–90.CrossRefPubMedGoogle Scholar
  84. 84.
    Di Stasi A, Tey S, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673–83.CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.SpringfieldUSA

Personalised recommendations